What is Health In Tech, Inc.'s earnings per share (EPS)?

Health In Tech, Inc. (HIT) reported diluted earnings per share of $0.02 for fiscal year 2025. This represents a 100.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Health In Tech, Inc. Financials

HIT

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Health In Tech, Inc. (HIT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI HIT FY2025 2026-05-14

Health In Tech’s growth engine is adding volume fast, but on a lower-margin mix that relies on tight cash collection.

In the latest year, revenue moved from $19.5M to $33.3M while gross margin compressed sharply. Operating cash flow still improved to $3.1M even though net margin stayed near 4.0%, which means the business is scaling in cash terms but each new dollar appears less lucrative than the earlier revenue base.

The prior year’s equity jump to $13.2M alongside only $3.9M of retained earnings shows the stronger balance sheet was built mostly by external capital, not accumulated profit. That left room for investment outflows without a squeezed short-term position: cash remained $7.7M and the current ratio was 3.1x, so expansion did not obviously depend on balance-sheet strain.

Recent cash conversion is better than headline profitability suggests, with operating cash flow at $3.1M versus net income of $1.3M in the latest year. At the same time, accounts receivable fell to $756K even as revenue reached $33.3M, suggesting growth was not being financed by slower collections or a buildup of unpaid customer balances.

Financial Health Signals

Financial Profile 49/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Health In Tech, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Growth

Health In Tech, Inc.'s revenue surged 71.0% year-over-year to $33.3M, reflecting rapid business expansion. This strong growth earns a score of 87/100.

Leverage

Health In Tech, Inc. carries a low D/E ratio of 0.35, meaning only $0.35 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 95/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Health In Tech, Inc.'s current ratio of 3.13 indicates adequate short-term liquidity, earning a score of 60/100. The company can meet its near-term obligations, though with limited headroom.

Returns

Health In Tech, Inc.'s ROE of 7.5% shows moderate profitability relative to equity, earning a score of 52/100. This is up from 5.1% the prior year.

Piotroski F-Score Neutral

5/9

Health In Tech, Inc. passes 5 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

2.45x

For every $1 of reported earnings, Health In Tech, Inc. generates $2.45 in operating cash flow ($3.1M OCF vs $1.3M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$33.3M

YoY+71.0%

Health In Tech, Inc. generated $33.3M in revenue in fiscal year 2025. This represents an increase of 71.0% from the prior year.

EBITDA

N/A

Net Income

$1.3M

YoY+90.7%

Health In Tech, Inc. reported $1.3M in net income in fiscal year 2025. This represents an increase of 90.7% from the prior year.

EPS (Diluted)

$0.02

YoY+100.0%

Health In Tech, Inc. earned $0.02 per diluted share (EPS) in fiscal year 2025. This represents an increase of 100.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$7.7M

YoY-2.3%

Health In Tech, Inc. held $7.7M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

62.8%

YoY-16.4pp

Health In Tech, Inc.'s gross margin was 62.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 16.4 percentage points from the prior year.

Operating Margin

N/A

Net Margin

3.8%

YoY+0.4pp

Health In Tech, Inc.'s net profit margin was 3.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 0.4 percentage points from the prior year.

Return on Equity

7.5%

YoY+2.4pp

Health In Tech, Inc.'s ROE was 7.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 2.4 percentage points from the prior year.

Capital Allocation

R&D Spending

$1.6M

YoY-44.2%

Health In Tech, Inc. invested $1.6M in research and development in fiscal year 2025. This represents a decrease of 44.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

HIT Income Statement

Metric	FY25	FY24	FY23
Revenue	$33.3M+71.0%	$19.5M+1.8%	$19.2M
Cost of Revenue	$12.4M+205.8%	$4.1M+75.9%	$2.3M
Gross Profit	$20.9M+35.6%	$15.4M-8.4%	$16.8M
R&D Expenses	$1.6M-44.2%	$2.8M+40.4%	$2.0M
SG&A Expenses	$13.7M+61.1%	$8.5M+4.9%	$8.1M
Operating Income	N/A	N/A	N/A
Interest Expense	N/A	$495K+24022.8%	$2K
Income Tax	$395K+80.9%	$219K-76.9%	$945K
Net Income	$1.3M+90.7%	$670K-83.1%	$4.0M
EPS (Diluted)	$0.02+100.0%	$0.01	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$8.8M+16.8%	$7.5M-11.6%	$8.5M-8.8%	$9.3M+16.2%	$8.0M+63.4%	$4.9M+10.0%	$4.5M-10.9%	$5.0M
Cost of Revenue	$4.3M+26.1%	$3.4M+1.0%	$3.3M+11.4%	$3.0M+12.9%	$2.7M+140.2%	$1.1M+13.0%	$980K+0.5%	$975K
Gross Profit	$4.5M+9.2%	$4.1M-19.7%	$5.1M-18.5%	$6.3M+17.8%	$5.4M+41.0%	$3.8M+9.1%	$3.5M-13.6%	$4.0M
R&D Expenses	$920K+331.9%	$213K-9.6%	$236K-59.5%	$583K+8.3%	$538K-15.1%	$634K-11.8%	$718K+2.4%	$702K
SG&A Expenses	$3.5M+8.7%	$3.2M-7.9%	$3.5M-8.6%	$3.8M+16.3%	$3.2M+14.0%	$2.8M+57.0%	$1.8M-0.2%	$1.8M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$165K0.0%	$165K
Income Tax	-$480K-240.0%	-$141K-195.4%	$148K-26.9%	$203K+9.0%	$186K+456.3%	$33K+9.0%	$31K-51.6%	$63K
Net Income	-$1.6M-425.0%	-$303K-166.9%	$452K-28.3%	$631K+26.5%	$499K+445.9%	-$144K-138.3%	$376K+11.3%	$338K
EPS (Diluted)	$-0.03	N/A	$0.010.0%	$0.010.0%	$0.01	N/A	$0.010.0%	$0.01

HIT Balance Sheet

Metric	FY25	FY24	FY23
Total Assets	$23.1M+46.4%	$15.8M+37.1%	$11.5M
Current Assets	$16.2M+49.9%	$10.8M+57.2%	$6.9M
Cash & Equivalents	$7.7M-2.3%	$7.8M+224.8%	$2.4M
Inventory	N/A	N/A	N/A
Accounts Receivable	$756K-54.1%	$1.6M-26.3%	$2.2M
Goodwill	N/A	N/A	N/A
Total Liabilities	$6.0M+130.0%	$2.6M-52.0%	$5.4M
Current Liabilities	$5.2M+142.0%	$2.1M-55.4%	$4.8M
Long-Term Debt	N/A	N/A	N/A
Total Equity	$17.1M+29.9%	$13.2M+116.1%	$6.1M
Retained Earnings	$5.2M+32.4%	$3.9M+20.5%	$3.3M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$29.0M+25.4%	$23.1M+1.5%	$22.8M+2.6%	$22.2M+4.0%	$21.3M+35.3%	$15.8M	N/A	N/A
Current Assets	$22.1M+36.7%	$16.2M+7.4%	$15.0M+1.3%	$14.9M-4.6%	$15.6M+44.4%	$10.8M	N/A	N/A
Cash & Equivalents	$10.3M+34.6%	$7.7M-4.4%	$8.0M-1.4%	$8.1M+7.4%	$7.6M-3.5%	$7.8M+349.2%	$1.7M-19.2%	$2.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$3.7M+394.2%	$756K-12.9%	$869K-32.2%	$1.3M-39.3%	$2.1M+28.1%	$1.6M	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$7.4M+23.2%	$6.0M+6.8%	$5.6M-2.7%	$5.8M-19.7%	$7.2M+175.8%	$2.6M	N/A	N/A
Current Liabilities	$7.0M+36.7%	$5.2M-1.6%	$5.2M-2.8%	$5.4M-20.2%	$6.8M+216.9%	$2.1M	N/A	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$21.6M+26.2%	$17.1M-0.3%	$17.2M+4.5%	$16.4M+16.0%	$14.2M+7.5%	$13.2M+90.6%	$6.9M+5.8%	$6.5M
Retained Earnings	$3.6M-30.4%	$5.2M-5.5%	$5.5M+8.9%	$5.1M+14.2%	$4.4M+12.7%	$3.9M	N/A	N/A

HIT Cash Flow Statement

Metric	FY25	FY24	FY23
Operating Cash Flow	$3.1M+44.0%	$2.2M+42.3%	$1.5M
Capital Expenditures	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A
Investing Cash Flow	-$3.1M-273.6%	-$837K+57.0%	-$1.9M
Financing Cash Flow	-$187K-104.6%	$4.1M+204.6%	$1.3M
Dividends Paid	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$3.3M-835.6%	$451K-33.1%	$674K-54.5%	$1.5M+180.9%	$527K+199.3%	-$531K-125.0%	$2.1M+67.5%	$1.3M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$362K+52.8%	-$768K-3.1%	-$745K+18.1%	-$910K-29.3%	-$703K-29.8%	-$542K-705.8%	-$67K+28.4%	-$94K
Financing Cash Flow	$6.3M+17060.6%	-$37K+14.5%	-$44K-429.5%	-$8K+91.6%	-$98K-101.4%	$7.2M+390.5%	-$2.5M-569.5%	-$369K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

HIT Financial Ratios

Metric	FY25	FY24	FY23
Gross Margin	62.8%-16.4pp	79.2%-8.8pp	88.0%
Operating Margin	N/A	N/A	N/A
Net Margin	3.8%+0.4pp	3.4%-17.2pp	20.7%
Return on Equity	7.5%+2.4pp	5.1%-59.9pp	65.0%
Return on Assets	5.5%+1.3pp	4.3%-30.2pp	34.4%
Current Ratio	3.13-1.9	5.06+3.6	1.43
Debt-to-Equity	0.35+0.2	0.20-0.7	0.89
FCF Margin	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	51.4%-3.6pp	55.0%-5.6pp	60.6%-7.2pp	67.8%+0.9pp	66.8%-10.6pp	77.4%-0.6pp	78.0%-2.5pp	80.5%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-18.1%-14.1pp	-4.0%-9.4pp	5.3%-1.4pp	6.8%+0.5pp	6.2%+9.2pp	-2.9%-11.4pp	8.4%+1.7pp	6.8%
Return on Equity	-7.3%-5.6pp	-1.8%-4.4pp	2.6%-1.2pp	3.8%+0.3pp	3.5%+4.6pp	-1.1%-6.5pp	5.4%+0.3pp	5.2%
Return on Assets	-5.5%-4.2pp	-1.3%-3.3pp	2.0%-0.9pp	2.8%+0.5pp	2.3%+3.3pp	-0.9%	N/A	N/A
Current Ratio	3.130.0	3.13+0.3	2.87+0.1	2.76+0.5	2.31-2.8	5.06	N/A	N/A
Debt-to-Equity	0.340.0	0.35+0.0	0.33-0.0	0.35-0.2	0.51+0.3	0.20	N/A	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

SoundThinking Inc SSTI

$85.8M

Duos Technologies Group Inc DUOT

$262.8M

Expensify, Inc. EXFY

$109.9M

Silvaco Group SVCO

$337.4M

Asure Software Inc ASUR

$244.7M

Frequently Asked Questions

What is Health In Tech, Inc.'s annual revenue?

Health In Tech, Inc. (HIT) reported $33.3M in total revenue for fiscal year 2025. This represents a 71.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Health In Tech, Inc.'s revenue growing?

Health In Tech, Inc. (HIT) revenue grew by 71% year-over-year, from $19.5M to $33.3M in fiscal year 2025.

Is Health In Tech, Inc. profitable?

Yes, Health In Tech, Inc. (HIT) reported a net income of $1.3M in fiscal year 2025, with a net profit margin of 3.8%.

What is Health In Tech, Inc.'s gross margin?

Health In Tech, Inc. (HIT) had a gross margin of 62.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Health In Tech, Inc.'s net profit margin?

Health In Tech, Inc. (HIT) had a net profit margin of 3.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Health In Tech, Inc.'s return on equity (ROE)?

Health In Tech, Inc. (HIT) has a return on equity of 7.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Health In Tech, Inc.'s operating cash flow?

Health In Tech, Inc. (HIT) generated $3.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Health In Tech, Inc.'s total assets?

Health In Tech, Inc. (HIT) had $23.1M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Health In Tech, Inc. spend on research and development?

Health In Tech, Inc. (HIT) invested $1.6M in research and development during fiscal year 2025.

What is Health In Tech, Inc.'s current ratio?

Health In Tech, Inc. (HIT) had a current ratio of 3.13 as of fiscal year 2025, which is generally considered healthy.

What is Health In Tech, Inc.'s debt-to-equity ratio?

Health In Tech, Inc. (HIT) had a debt-to-equity ratio of 0.35 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Health In Tech, Inc.'s return on assets (ROA)?

Health In Tech, Inc. (HIT) had a return on assets of 5.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Health In Tech, Inc.'s Piotroski F-Score?

Health In Tech, Inc. (HIT) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Health In Tech, Inc.'s earnings high quality?

Health In Tech, Inc. (HIT) has an earnings quality ratio of 2.45x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Health In Tech, Inc.?

Health In Tech, Inc. (HIT) scores 49 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.